US 12,403,143 B2
Pharmaceutical composition for treating functional psychiatric disorders
Margarita Alekseevna Morozova, Moscow (RU); Allan Gerovich Beniashvili, Moscow (RU); Maksim Eduardovich Zapolsky, Moskovskaya obl. (RU); and Vladimir Viktorovich Nesteruk, Moscow (RU)
Appl. No. 16/082,090
Filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU “VALENTEK”, Moscow (RU)
PCT Filed Nov. 15, 2016, PCT No. PCT/RU2016/000783
§ 371(c)(1), (2) Date Sep. 4, 2018,
PCT Pub. No. WO2017/151006, PCT Pub. Date Sep. 8, 2017.
Claims priority of application No. RU2016107968 (RU), filed on Mar. 4, 2016.
Prior Publication US 2019/0275059 A1, Sep. 12, 2019
Int. Cl. A61P 25/18 (2006.01); A61K 31/5513 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/5513 (2013.01) [A61P 25/18 (2018.01); A61P 25/24 (2018.01)] 8 Claims
 
1. A method of treatment of a condition requiring selective inhibition of D4 and 5HT2A receptors, comprising administering to a patient a pharmaceutical composition containing a compound that is 11-(4-methylpiperazine-1-yl)-7-fluoro-8-chloro-5Hdibenzo[b,e][1,4]diazepine of formula (I):

OG Complex Work Unit Chemistry
in an amount effective as a selective antagonist of D4 and 5HT2A receptors, and at least one pharmaceutically acceptable carrier;
wherein the condition requiring selective inhibition of D4 and 5HT2A receptors is impulsivity or pathological gambling disorder.